Human T cell leukemia virus type III antibody, lymphadenopathy, and acquired immune deficiency syndrome in hemophiliac subjects. Results of a prospective study

Joan K. Kreiss , Lynn W. Kitchen , Harry E. Prince , Carol K. Kasper
The American Journal of Medicine 80 ( 3) 345 -350

29
1986
Immune response and epitope mapping of a candidate HIV-1 p17 vaccine HGP30.

Charles A. B. Boucher , Willy J. A. Krone , Jaap Goudsmit , Rob H. Meloen
Journal of Clinical Laboratory Analysis 4 ( 1) 43 -47

23
1990
2001
Tu1484 – Hepatitis C Screening in the Colonoscopy Suite: Patients are There, Why Don't We Screen Them?

Ahmad Abu-Heija , Bashar Mohamad , Maher Tama , Pradeep R. Kathi
Gastroenterology 156 ( 6)

2019
Preclinical studies with IRX-2 and thymosin α1 in combination therapy

Paul H. Naylor , John W. Hadden
Annals of the New York Academy of Sciences 1194 ( 1) 162 -168

6
2010
Diagnostic assays for human immunodeficiency virus infection and for clinical progression by use of synthetic p17 peptide epitopes

Paul H. Naylor , Angela Heithaus , Ashey Kale , Michael R. Erdos
Monographs in virology 18 74 -90

1990
Melanocyte-stimulating hormone and prolactin secretion in cell culture of estrogen-induced pituitary tumors in the hamster.

Douglas C. Peebles , Rabinder N. Kurl , Janet M. Loring , Paul H. Naylor
Journal of Steroid Biochemistry 19 ( 5) 1557 -1562

1983
Circulating thymulin and thymosin-α1 activity in pediatric acquired immune deficiency syndrome: In vivo and in vitro studies

Arye Rubinstein , Brian E. Novick , Marc J. Sicklick , Larry J. Bernstein
The Journal of Pediatrics 109 ( 3) 422 -427

18
1986
Thymus-Derived Peptides in the Treatment of Viral Chronic Hepatitis

Paul H. Naylor , Milton G. Mutchnick
Digestive Diseases 14 ( 6) 362 -370

10
1996
Thymosin in the early diagnosis and treatment of high risk homosexuals and hemophiliacs with AIDS-like immune dysfunction.

Paul H. Naylor , Richard S. Schulof , Marcelo B. Sztein , Thomas J. Spira
Annals of the New York Academy of Sciences 437 ( 1) 88 -97

17
1984
T cell targeted immune enhancement yields effective T cell adjuvants

Paul H. Naylor , John W. Hadden
International Immunopharmacology 3 ( 8) 1205 -1215

39
2003
Thymosin α1 does not promote growth or oncogenic transformation

Paul H. Naylor , Mitchell R. Smith , Milton G. Mutchnick , Cartha W. Naylor
International Journal of Immunopharmacology 18 ( 5) 321 -327

2
1996
Improved ELISA to measure thymosin α1: Comparison of whole and absorbed antisera

Seiji Wada , Paul H. Naylor , Cartha W. Naylor , Allan L. Goldstein
International Journal of Immunopharmacology 10 ( 7) 795 -801

10
1988
Preclinical and clinical studies on immunogenicity and safety of the HIV-1 p17-based synthetic peptide AIDS vaccine--HGP-30-KLH.

Paul H. Naylor , Marcelo B. Sztein , Saiji Wada , Scott Maurer
International Journal of Immunopharmacology 13 117 -127

36
1991
Identification of immunoreactive forms of thymosin α1 in serum and supernatants by combining HPLC and RIA

Paul H. Naylor , Karen K. Oates , Marcia C. Coss , Michael R. Erdos
International Journal of Immunopharmacology 14 ( 7) 1267 -1278

10
1992
2015
Diminished thymosinalpha‐1levels in persons exposed to 2,3,7,8‐tetrachlorodibenzo‐p‐dioxin

Paul A. Stehr‐Green , Paul H. Naylor , Richard E. Hoffman
Journal of Toxicology and Environmental Health 28 ( 3) 285 -295

14
1989
Thymosin-α1, but not interferon-α, specifically inhibits anchorage-independent growth of hepatitis B viral transfected HepG2 cells

Jeffrey A. Moshier , Milton G. Mutchnick , Julie Dosescu , Todd K. Holtz
Journal of Hepatology 25 ( 6) 814 -820

10
1996
A short course of neoadjuvant IRX-2 induces changes in peripheral blood lymphocyte subsets of patients with head and neck squamous cell carcinoma.

Theresa L. Whiteside , Lisa H. Butterfield , Paul H. Naylor , James E. Egan
Cancer Immunology, Immunotherapy 61 ( 6) 783 -788

8
2012